Contents

Search

sotorasib (Lumakras)

Indications: - treatment of - non-small cell lung cancer (NSCLC)* or colorectal carcinoma with KRAS p.G12C mutation * FDA-approved Dosage: - escalation 80, 360, 720, & 960 mg PO QD - 21 day cycles Notes: - KRAS p.G12C mutation is present in 13% of NSCLC & 1-7% of colorectal cancers

General

small inhibitory antineoplastic agent (ib drug)

References

  1. Osterweil N Sotorasib Is a 'Triumph of Drug Discovery'in Cancer Medscape - Sep 21, 2020 https://www.medscape.com/viewarticle/937730 - Hong DS, Fakih MG, Strickler JH et aL KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med 2020; 383:1207-1217. Sept 24. PMID: 32955176 https://www.nejm.org/doi/full/10.1056/NEJMoa1917239
  2. Chustecka Z First Drug for Lung Cancer With KRAS Mutation Gains FDA Approval. Medscape - May 28, 2021. https://www.medscape.com/viewarticle/952091